<DOC>
	<DOC>NCT02215252</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)</brief_summary>
	<brief_title>A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)</brief_title>
	<detailed_description />
	<mesh_term>Pain</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Men and women aged 18 years to 80 years. Diagnosis of Type 2 diabetes mellitlus (T2DM) with current glycosylated hemoglobin A1c (HbA1c) levels of â‰¤ 11% at Screening and on a stable antidiabetic medication regimen for at least 30 days prior to randomization. Presence of ongoing pain due to DPN for at least 6 months. Willing to discontinue protocolspecified prohibited pain medications for DPN throughout the duration of the study. Painful neuropathies or painful conditions other than DPN that may confound evaluation of pain due to DPN during the study. Subjects who have failed previously on pregabalin (at the recommended label dose and for adequate duration) due to lack of efficacy. Subjects with any clinically significant medical or psychiatric conditions or clinically significant laboratory test abnormalities. Pregnant women, lactating mothers, men with partners currently pregnant, women suspected of being pregnant, and women who wish to be pregnant during the course of the clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>